Is Gabapentin Effective in Reducing Heavy Drinking and Alcohol Related Insomnia in Alcohol Dependent Patients? by Michalsky, Benjamin
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2019
Is Gabapentin Effective in Reducing Heavy
Drinking and Alcohol Related Insomnia in Alcohol
Dependent Patients?
Benjamin Michalsky
Philadelphia College of Osteopathic Medicine
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Substance Abuse and Addiction Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Michalsky, Benjamin, "Is Gabapentin Effective in Reducing Heavy Drinking and Alcohol Related Insomnia in Alcohol Dependent









Is gabapentin effective in reducing heavy drinking and alcohol 








Benjamin Michalsky, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
















OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is 
gabapentin effective in reducing heavy drinking and alcohol related insomnia in alcohol 
dependent patients?” 
 
STUDY DESIGN: Review of three English language primary studies, one published in 2008 and 
two others in 2013.  
 
DATA STUDIES: Three double blind, randomized controlled trials (RCTs) analyzing the effects 
of gabapentin therapy in attempting to reduce heavy drinking and alcohol related insomnia in 
alcohol dependent patients were found via PubMed and Cochrane databases.  
 
OUTCOMES MEASURED: The reduction in alcohol consumption and improvement in alcohol 
related insomnia were measured through the Clinical Institute Withdrawal Assessment for 
Alcohol (CIWA-Ar), Penn Alcohol Craving Scale (PACS), Epworth daytime sleepiness scale, 
overnight polysomnography (PSG), sleep problem questionnaire, and drinking diaries. 
 
RESULTS: The three double blind RCTs by Brower, Mason, and Stock showed a statistically 
significant reduction in heavy drinking and alcohol related insomnia at the endpoint of 
intervention. 
 
CONCLUSION: The RCTs by Brower, Mason, and Stock provided compelling evidence that 
gabapentin is an effective treatment for heavy drinking in alcohol dependent patients and 
minimizing alcohol related insomnia.  
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INTRODUCTION 
 Alcohol abuse and dependence according to the DSM-V criteria is classified as a 
problematic pattern of alcohol use leading to clinically significant impairment or distress, as 
manifested by multiple psychosocial, behavioral, or physiologic features.1 It’s known that 
alcohol dependency and abuse is commonly associated with psychological issues that has an 
impact on social well-being and quality of life. Heavy drinking is defined as consuming; 15 or 
more drinks per week for men and 8 or more for women.2 There are numerous medical 
consequences of alcohol abuse that can affect almost every organ system such as trauma/injury, 
anxiety/depression, hypertension, GI, cardiac, and neurologic symptoms, electrolyte and sleep 
disturbances, increased liver enzymes, and social or legal problems. There are various treatments 
for alcohol abuse and dependency but most patients are refractory to them and relapse soon after 
attempted treatment.3  
 There are an estimated 4-40% of medical and surgical patients that have experienced 
problems related to alcohol.4 More than 88,000 deaths/year in the US are directly attributed to 
alcohol use.4 Heavy drinking has led to 2.5 million years of potential life lost (YPLL) each year 
in the US from 2006-2010.3 It has shortened the lives of those who died by an average of 30 
years and is responsible for 1 in 10 deaths among working-age adults 20-64 years old.3 In the 
United States alone, the cost of excessive alcohol use reach $249 billion in 2010.4 The total 
amount of total health care loss is $23.79 billion (11% of the total $249 billion).4 From 2006-
2014, there was a 47% increase in all alcohol-related emergency department (ED) visits which 
translated to an average annual increase of 210,000 alcohol-related ED visits.5 The use of 
pharmacological treatments can help decrease heavy drinking and provide a better quality of life 
for those who suffer with alcohol dependency.  
Michalsky, gabapentin & alcohol use 2 
 
 Alcohol dependence is a chronic disease that is associated with malnutrition, trauma, and 
various central nervous system conditions. The pathogenesis of alcohol use and abuse is not 
known, but genetics, environmental influences, specific personality traits, and cognitive 
functioning all play a role. It’s estimated that genetic factors are responsible for roughly 50% of 
the vulnerabilities related to alcohol use disorder.6 There are multiple environmental factors such 
as intra-familial influences including peer influences, prenatal exposure, and parenting patterns. 
Phenotypes such as neuroticism, extroversion, and impulsivity are associated with alcohol use as 
well as cognitive dysfunction.6 It has also been shown that alcohol abuse is more prevalent in 
those affected with severe disabilities, other substance use disorders, and various mood 
disorders.1 It has been recommended that adults be screened for unhealthy alcohol use.4  
 The treatment for alcohol dependence begins with abstinence. Most are refractory to this 
type of treatment so further pharmaceutical and supportive therapies are used in attempt to 
reduce heavy drinking.4 Pharmaceutical options include opioid antagonists (naltrexone), N-
methyl-D-aspartate (NMDA) receptor antagonists (acamprosate), enzyme inhibitors (disulfiram), 
vitamins (B1-thiamine), electrolytes (magnesium), anti-convulsants (gabapentin and topiramate), 
and supportive therapy (psychotherapy and rehabilitation programs).7 The method being 
analyzed in this study is a pharmaceutical approach for those attempting to reduce their heavy 
drinking and alcohol related insomnia. Gabapentin is mostly used as an anti-convulsant but can 
also be used as an analgesic and anxiolytic to treat a wide variety of conditions such as 
fibromyalgia, neuropathic pain, postherpetic neuralgia, hot flashes, restless leg syndrome, 
seizures, and social anxiety.8 It is a drug that blocks voltage-dependent calcium channels by 
binding to its alpha-2-delta subunit.8 It increases cerebral GABA levels and may modulate the 
release of glutamate and norepinephrine which may explain its potential to improve sleep, reduce 
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anxiety, and prevent relapse.8 The potential efficacy of gabapentin to prevent relapse is 
particularly notable because it has a low addictive potential, doesn’t undergo hepatic metabolism, 
has few interactions with other medications, is safe when combined with alcohol, and isn’t 
associated with fatal overdoses when taken alone.8 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Is gabapentin 
effective in reducing heavy drinking and alcohol related insomnia in alcohol dependent 
patients?” 
METHODS 
 The articles were searched for and discovered via PubMed and Cochrane Library. They 
were chosen based on their relevance to the clinical question and if they had patient oriented 
outcomes (POEMs). The three studies utilized in this review include three double blind RCTs 
and all contained POEMs. The population consisted of male and female patients that were 
alcohol dependent and 18 years or older. The intervention used was oral gabapentin versus the 
control group, a placebo in two trials (Brower9 & Mason8) and chlordiazepoxide in the other 
(Stock10). The outcome measured in all three studies was improvement of heavy drinking and 
alcohol related insomnia. Key words used to discover the literature included gabapentin and 
alcohol use. All three articles were published in the English language in peer review journals. 
Inclusion criteria for this study consisted of alcohol dependent patients who were 18 years or 
older. Exclusion criteria consisted of individuals under 18 years old, pregnant females, patients 
who do not suffer from alcohol dependence, and those with an underlying psychiatric illness. 
Summary of the statistics used include relative benefit increase (RBI), absolute benefit increase 
(ABI), numbers needed to treat (NNT), relative risk (RR), Cox Regression, Fisher’s Exact Test, 
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confidence interval (CI), and p-values. This paper evaluates three randomized controlled trials 
comparing the efficacy of gabapentin in attempt to reduce heavy drinking and alcohol related 
insomnia in alcohol dependent patients. 
Table 1 – Demographics & Characteristics of Included Studies  





21 > 18 
years old 
- Met DSM-IV criteria 
for alcohol dependence 
- Hx of insomnia for >6 
months 
- A desire to abstain 
from alcohol  
- Pregnant or nursing 
women 
- < 18 years old  
- If insomnia is due to 
a medication 
- If subject was taking 
anti-depressant 
7 - Regimen of either 
oral Gabapentin 300 
mg or Placebo 300 
mg before bed with 
final target dose of 






150 > 18 
years old 
- Met DSM-IV criteria 
for alcohol dependence 
- Abstinent from 
alcohol 3 days prior to 
randomization 
- CIWA-Ar score > 9. 




- Positive urine drug 
screen 
- Psychiatric disease 
65 - Regimen of oral 
gabapentin (dosages 
of 0 [placebo], 900 
mg or 1800 mg) 





26 > 18 
years old 
- Met DSM-IV criteria 
for alcohol withdrawal 
- Was a military veteran 
- Unstable medical or 




- On medication that 
affects alcohol 
dependence  
9 - Regimen of  oral 
gabapentin 1200 mg 
or chlordiazepoxide 
100 mg: days 1-3, 
900 mg or 75 mg 
day 4, 600 mg or 50 
mg day 5, and 300 
mg or 25 mg day 6.  
 
OUTCOMES MEASURED  
 All outcomes measured in the three trials were based on POEMs that determined the 
efficacy of gabapentin in the reduction of alcohol consumption and improvement in alcohol 
related insomnia. Reduction in alcohol consumption was measured by using Clinical Institute 
Withdrawal Assessment for Alcohol (CIWA-Ar), Penn Alcohol Craving Scale (PACS), Epworth 
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RESULTS 
 Brower9 studied 21 patients 18 years or older from outpatient alcohol treatment centers or 
the surrounding community via advertising. During the screening process, 35 participants were 
selected but 14 were excluded. This was a double-blinded RCT that consisted of a 1-2 week 
screening phase followed by a 6 week trial of gabapentin vs. placebo, and a 6 week post trial 
follow-up visit. Eleven patients were given a placebo and ten were given gabapentin. During the 
trial, medication was titrated to 5 capsules of either oral gabapentin or placebo 45 minutes prior 
to bedtime over a 10-day period as tolerated. The active medication, gabapentin, contained 300 
mg with a final target dose of 1500 mg prior to bedtime over five days then tapered down over a 
4-day period.  
 The primary drinking outcome variable was survival in days to the first episode of heavy 
drinking starting at zero days. Drinking outcomes during the first six weeks couldn’t be verified 
for 6 of the 7 non-completers (2 gabapentin subjects) so they were classified as heavy drinkers. 
Cox Regression and Fisher’s exact test were used for baseline variables that correlated with time 
to heavy drinking (Table 2). Another variable was complete abstinence from alcohol. Three 
(30%) of the ten gabapentin subjects relapsed to heavy drinking compared to nine (81.8%) of 
eleven in the placebo group by week six (Fisher’s exact test, p=0.03). Survival analysis was 
conducted that showed a significant difference (p=0.03) favoring the gabapentin group. 
Adjusting for relative risk of relapse to heavy drinking, the gabapentin group was much lower 
(Cox regression, RR=0.25, p=0.047). Six (60%) of ten subjects in the gabapentin group relapsed 
to heavy drinking by week 12 versus eleven (100%) of the eleven in the placebo group (Fisher’s 
exact test, p=0.04). Survival analysis at 12 weeks again favored the gabapentin group (p=0.003). 
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It showed that bedtime administration of gabapentin had a positive effect and significantly 
delayed onset of relapse in alcohol dependent patients at both 6 and 12 weeks. 
Table 2 (Brower9): Survival to relapse of heavy drinking 
Patients without relapse to 
heavy drinking 
Relative risk reduction 
(RRR) 
Absolute risk reduction 
(ARR) 






2.85 51.8% 1.93 
 
 Cox Regression P-value Fisher’s exact test 
Gabapentin group  RR=0.25 P=0.047 P=0.03 
 
 Mason8 studied 150 patients 18 years or older who were treatment-seeking volunteers 
with alcohol dependence at The Scripps Research Institute in La Jolla, CA where they provide a 
broad range of medical services. The study was approved by the Scripps institutional review 
board (IRB). This was a double blind RCT that had weekly visits through the first 12 weeks as 
well as at 13 and 24 weeks post treatment. Simple randomization procedures were followed and 
assigned participants with oral gabapentin, 900 mg or 1800 mg, or a placebo. Subjects were 
provided weekly medication; each package contained two identical capsules to be taken three 
times a day. In the active group, the placebo was replaced with an identical 300 mg capsule on 
the evening of day 1, morning of day 2, afternoon of day 3, and on a similar schedule each day 
until the assigned fixed dose of 900 mg was achieved on day 4 or 1800 mg on day 6. These 
participants were maintained on the assigned dose until week 11 and were titrated off in reverse 
order of initial titration dose. Analysis of mean abstinence duration was based on the rate of 
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complete abstinence over the 12-week study as well as the rate of no heavy drinking over the 12-
week trial.  
 In Mason’s study, 185 subjects were assessed for eligibility but 35 were excluded (19 
ineligible and 16 declined to participate). The mean time in study, rate of study completion, and 
medication compliance didn’t differ among treatment groups, nor did the reasons for termination. 
Upon completion, gabapentin had a significant linear dose effect in increasing the rates of 
complete abstinence (X2= 5.39, p=0.02) over the 12-week course of treatment relative to the 
placebo group. The rate of sustained 12-week abstinence was 4.1% (95% CI, 1.1-13.7%) in the 
placebo group, 11.1% (95% CI, 5.2-22.2%) in the 900 mg group, and 17.0% (95% CI, 8.9-
30.1%) in the 1800 mg group. Gabapentin 1800 mg had the greatest treatment effect with a 
number needed to treat (NNT) of 8 and an odds ratio (OR)= 4.8 (95% CI, 0.9-35.0), which 
indicated a large effect size for abstinence. The rate of no heavy drinking was 44.7% (95% CI, 
31.4-58.8%) in the 1800 mg group, 29.6% (95% CI, 19.1-42.8%) in the 900 mg group, and 
22.5% (95% CI, 13.6-37.2%) in the placebo group. The 1800 mg had a NNT of 5 and OR=2.8 
(95% CI, 1.1-7.5), indicating a medium effect size for no heavy drinking. Gabapentin also 
showed significant linear decreases in the average number of days of heavy drinking per week 
and number of drinks consumed per week. Drinking outcomes were evaluated for the 65 
participants who completed both the 12-week trial and the 24-week follow-up visit. Significant 
linear dose effects were sustained at week 24 for rate of complete abstinence (X2=4.73, p=0.02), 
number of heavy drinking days per week (t= -3.09, p=0.002) with an insignificant trend for rate 
of no heavy drinking (X2=6.43, p=0.06). Beneficial effects of gabapentin for treatment of alcohol 
dependence were found over the 12-week course of treatment on rates of complete abstinence 
and no heavy drinking, with the greatest effects seen in the 1800 mg group. 
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Table 3 (Mason8): Rates of no heavy drinking  
 Rate (%) 95% CI CER EER RBI ABI NNT 
Gabapentin 1800 mg 44.7% 31.4-58.8% 0.225 0.447 0.987 0.222 5 
Gabapentin 900 mg 29.6% 19.1-42.8% 0.225 0.296 0.316 0.07 15 
Placebo 22.5% 13.6-37.2%      
 
Stock10 studied 26 subjects who were veterans, 18 years or older and who met the DSM-
IV criteria for alcohol withdrawal. This was a double blind RCT, double-dummy 7-day trial 
comparing gabapentin to chlordiazepoxide. Gabapentin 300 mg and chlordiazepoxide 25 mg 
were put into a 7-day medication package and distributed to the subjects. The titration dosing 
was as followed either gabapentin 1200 mg or chlordiazepoxide 100 mg orally days 1-3, 900 mg 
or 75 mg day 4, 600 mg or 50 mg day 5, and 300 mg or 25 mg day respectively. Each dose 
consisted of one active medication capsule and one placebo capsule. Additionally, all subjects 
received prescriptions for multiple vitamins, folic acid 1 mg, and thiamine 100 mg. Subjects 
were required to meet every weekday with the clinicians, which included a CIWA-Ar, ESS, 
PACS, and mental status exam. 
 Initially, the study had 104 subjects but due to significant changes in the VA’s emergency 
department and mental health department policies, the study was limited to 26 subjects. There 
were 429 detoxification clinic patients screened but 403 patients were excluded, leaving 26 
subjects (25 males and 1 female) who met criteria. Comparisons were made during the early 
stage (days 1-4) and the late stage (days 5-7), assessing CIWA-Ar, ESS, and PACS. After 
randomization, 17 subjects were given gabapentin and 9 were given chlordiazepoxide. Baseline 
ESS scores were well balanced between both groups (6.2 in gabapentin group and 4.7 in 
chlordiazepoxide). Baseline ESS did not correlate significantly with baseline BAC (Pearson 
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R=0.30, p=0.14). The adjusted mean ESS did not differ much between groups during the early 
stage; the ESS was 0.66 higher in the gabapentin group when compared to the chlordiazepoxide 
group; (95% CI -1.93 to 3.26; p=0.61). During the late stage, the adjusted mean ESS score was 
lower with gabapentin (mean difference -3.70; 95% CI -7.21 to -0.19; p=0.04). The adjusted 
mean PACS score didn’t differ between groups during the early stage (1.39 lower with 
gabapentin; 95% CI -6.48 to 3.70; p=0.59). During the late stage, there was a trend toward a 
lower adjusted mean PACS score in the gabapentin group (mean difference=6.05; 95% CI -12.82 
to 0.72; p=0.08). CIWA-Ar scores averaged 7.7 (gabapentin) and 8.8 (chlordiazepoxide) at 
baseline (range 0-20) and were well balanced between the groups (p=0.64). Both groups showed 
reduction during the 7-day trial, with gradual reduction in withdrawal symptoms severity. 
Mixed-model analysis showed no significant difference in adjusted follow-up mean scores 
between the groups in the early or late stage.  
Table 4 (Stock10): Results for Early and Late Stage Treatment  
 Early stages (Days 1-4): Late stage (Days 5-7) 
 Gabapentin Chlordiazepoxide (95% CI)   
p-value 
Gabapentin Chlordiazepoxide (95% CI) 
p-value 
ESS 5.97 5.31 0.61 2.65 6.35 0.04 
PACS 15.66 17.05 0.59 10.74 16.78 0.08 
CIWA-Ar 5.86 6.64 0.60 4.33 3.29 0.62 
 
DISCUSSION 
 Brower’s study showed that bedtime administration of gabapentin significantly delayed 
the onset of relapse in alcohol dependent patients selected for clinical insomnia at 6 and 12 
weeks.9 Complete abstinence from drinking wasn’t associated with those taking gabapentin but 
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the proportion of subjects that relapsed to heavy drinking was smaller in the gabapentin group at 
the end of treatment. However, caution needs to be exercised, as this was a pilot study with a 
small sample size. Two major limitations were a lack of funds that hindered recruitment for a 
larger sample size and the study didn’t consist of subjects who didn’t suffer from insomnia. The 
high attrition rate (7 of 21 subjects at 6 weeks) was another limitation that could have been due 
to payments for which $150 of the total reimbursement ($325) could be obtained by week 3 of 
the study.9 
Mason’s study demonstrated beneficial effects of gabapentin for the treatment of alcohol 
dependence over the 12 week course of treatment on the rates of complete abstinence and no 
heavy drinking.8 The best results were found in those subjects who were given the maximum 
amount of gabapentin (1800 mg). It had a favorable safety profile, and there were no unexpected 
or serious drug related adverse events or differences in study discontinuation rates owing to 
adverse events.8 This study showed that the subjects symptoms of sleep disturbance and related 
daytime dysfunction significantly improved with gabapentin relative to the placebo. Gabapentin 
effectively treated alcohol dependence and relapse associated symptoms involving craving, 
mood, and sleep.8 It has been used by physicians for other indications resulting in familiarity 
with its pharmacology, pharmacokinectics, and adverse effects which has allowed gabapentin to 
be used more readily for alcohol dependence.8 
 Stock’s study showed that subjects who received a fixed dose tapering regimen of 
gabapentin to treat alcohol withdrawal experienced significantly reduced daytime sleepiness but 
an insignificant trend toward reduction in alcohol craving by the end of their treatment period 
compared to those who took chlordiazepoxide.10 Dropout rates were similar for both groups. 
This trial demonstrated that gabapentin is a better alternative for benzodiazepines due to 
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speculation that it may dampen kindling (neural sensitization leading to progressive worsening of 
subsequent withdrawal episodes), is safer, less likely to interact with or increase sedation if 
alcohol is consumed, and may be as effective as benzodiazepines in treating alcohol 
withdrawal.10 One of the major limitations was the sample size, however, after reassignment of 
the study outcome measures and statistical analysis plan, the size was sufficient to determine 
treatment effect of ESS and PACS scores.10 Although there was a trend toward treatment effect 
on the PACS score, the difference seen in this small sample size didn’t reach significance.10 It 
supports gabapentin as a tolerable medication that is less sedating, leads to less cravings in 
outpatients treated for alcohol withdrawal but due to the small sample size, there isn’t enough 
information to generalize these results.10 
CONCLUSION 
 Based on the three RCTs reviewed, there is convincing data supporting the benefits and 
efficacy of using gabapentin to reduce heavy drinking and alcohol related insomnia in alcohol 
dependent patients. Studies showed that most patients would abstain from heavy drinking during 
the clinical trial as well as up to one month after completion of the trial. However, further studies 
should include those who don’t suffer from insomnia and assess for discontinuation syndromes. 
Testing gabapentin alone and in combination with cognitive-behavioral therapy for insomnia will 
also be important, given the early success of the latter in treating alcohol-dependent subjects. 
Larger studies with a more diverse population of patients with alcohol dependence were 
suggested to extend and replicate the findings. If these factors were taken into account then one 
could more assuredly say that gabapentin is effective in reducing or eliminating heavy drinking 
and alcohol related insomnia in alcohol dependent patients 
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